Cisen Pharmaceutical Co., Ltd. provided earnings guidance for the first quarter of 2018. The company predicts that the net profit belonging to shareholders of the listed company in the first quarter of 2018 will be between RMB 112,720,900 and RMB 122,968,300, which is expected to increase by between RMB 61,484,100 and RMB 71,731,500 with an increase of between 120% and 140% compared with the same period of the year before. The net profit belonging to shareholders of the listed company after excluding extraordinary profit and loss will be between RMB 112,449,500 and RMB 121,445,400, which is expected to increase by between RMB 67,475,700 and RMB 76,465,600 with an increase of between 150% and 170% compared with the same period of the year before.